Table S2. CDAI “Near Remission” Responses at Week 12 Based on Different CDAI Thresholds

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Week 12 CDAI Thresholds for Response** | **Placebo**  **(N=144)** | **250 mg q.d. CCX282-B**  **(N=98)** | **250 mg b.i.d. CCX282-B**  **(N=96)** | **500 mg q.d. CCX282-B**  **(N=97)** |
| CDAI ≤ 155 | 39 (27.1%) | 25 (25.5%) | 25 (26.0%) | 31 (32.0%) |
| CDAI ≤ 160 | 41 (28.5%) | 25 (25.5%) | 25 (26.0%) | 34 (35.1%) |
| CDAI ≤ 165 | 41 (28.5%) | 25 (25.5%) | 25 (26.0%) | 36 (37.1%) |
| CDAI ≤ 170 | 41 (28.5%) | 26 (26.5%) | 28 (29.2%) | 37 (38.1%) |